Ampollini Luca, Gnetti Letizia, Goldoni Matteo, Viani Lorenzo, Faedda Elisabetta, Campanini Nicoletta, Caruana Pietro, Crafa Pellegrino, Negri Francesca, Pucci Francesca, Leonardi Francesco, Ventura Luigi, Balestra Valeria, Braggio Cesare, Bocchialini Giovanni, Del Rio Paolo, Silini Enrico Maria, Carbognani Paolo, Rusca Michele
Thoracic Surgery, Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy.
Pathology Unit, Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy.
J Thorac Dis. 2017 Oct;9(Suppl 12):S1282-S1290. doi: 10.21037/jtd.2017.07.100.
Pulmonary metastasectomy is considered a standard procedure in the treatment of metastatic colorectal cancer (CRC). Different prognostic factors including multiple metastatic nodules, the presence of extra-pulmonary metastases and BRAF mutation status have been associated with poor survival. The aim of this study was to evaluate which factors influenced survival in CRC patients undergoing pulmonary metastasectomy by studying primary tumors and pulmonary metastases.
All patients treated for primary CRC who presented pulmonary metastases in a 10-year period were considered (group A). A control group treated for primary CRC who did not develop any pulmonary or extra-pulmonary metastases was taken for comparison (group B). Different prognostic factors including gender, age, tumor location, histological type, inflammatory infiltrate, BRAF, CDX2 and extra-pulmonary metastases were analyzed. Overall survival (OS) and patients' survival after pulmonary metastasectomy were also considered.
Fifty-four patients were evaluated in group A and twenty-three in group B. In group A, BRAF immunohistochemistry did not significantly differ between primary tumors and pulmonary metastases; no difference of BRAF expression was found between group A and B. Even the expression of CDX2 was not significantly different in primary tumors and metastases. Similarly, in group B CDX2 did not significantly differ from primary CRC of group A. The most significant prognostic factor was the presence of extra-pulmonary metastases. Patients with extra-pulmonary metastases experienced a significant shorter survival compared to patients with pulmonary metastases alone (P=0.001 with log-rank test P=0.003 with univariate Cox regression). Interestingly, patients with right pulmonary metastases presented a significant longer survival than those with left pulmonary metastases (P=0.027 with log-rank test 0.04 with univariate Cox regression).
The main prognostic factor associated with poor survival after lung resection of CRC metastases is a history of extra-pulmonary metastases. BRAF and CDX2 did not have a significant role in this small series of patients.
肺转移瘤切除术被认为是转移性结直肠癌(CRC)治疗的标准术式。包括多个转移结节、肺外转移的存在以及BRAF突变状态等不同的预后因素都与较差的生存率相关。本研究的目的是通过研究原发性肿瘤和肺转移瘤来评估哪些因素影响接受肺转移瘤切除术的CRC患者的生存。
纳入所有在10年期间因原发性CRC出现肺转移而接受治疗的患者(A组)。选取一组因原发性CRC接受治疗但未发生任何肺或肺外转移的对照组进行比较(B组)。分析不同的预后因素,包括性别、年龄、肿瘤位置、组织学类型、炎症浸润、BRAF、CDX2和肺外转移。还考虑了总生存期(OS)和肺转移瘤切除术后患者的生存期。
A组评估了54例患者,B组评估了23例患者。在A组中,原发性肿瘤和肺转移瘤之间BRAF免疫组化无显著差异;A组和B组之间未发现BRAF表达的差异。CDX2在原发性肿瘤和转移瘤中的表达也无显著差异。同样,在B组中,CDX2与A组的原发性CRC无显著差异。最显著的预后因素是肺外转移的存在。与仅发生肺转移的患者相比,发生肺外转移的患者生存期显著缩短(对数秩检验P = 0.001,单因素Cox回归P = 0.003)。有趣的是,右肺转移患者的生存期明显长于左肺转移患者(对数秩检验P = 0.027,单因素Cox回归P = 0.04)。
CRC转移瘤肺切除术后生存率差的主要预后因素是肺外转移史。在这一小部分患者中,BRAF和CDX2没有显著作用。